MAXIMUS (MMS) Lifted to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of MAXIMUS (NYSE:MMS) from a sell rating to a hold rating in a research note issued to investors on Wednesday morning.

According to Zacks, “MAXIMUS, Inc. is an extremely dynamic and complex organization that offers government and industry a range of unique services, products, and solutions. The diverse services and products that MAXIMUS offers may be categorized into three groups: Government Program Management and Operations, Consulting, and Systems. Government Program Management and Operations focuses on having a measurable impact on the lives of the citizens we help government serve. The insights of MAXIMUS Consulting, and the technological innovations advanced through Systems, help government gain program efficiencies and pursue improvements that in turn benefit citizens. “

Separately, Canaccord Genuity reduced their target price on shares of MAXIMUS from $62.00 to $61.00 and set a hold rating for the company in a research note on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $65.60.

Shares of MAXIMUS (NYSE:MMS) traded up $0.51 during midday trading on Wednesday, reaching $70.09. 610,421 shares of the company were exchanged, compared to its average volume of 316,889. The firm has a market cap of $4,565.45, a price-to-earnings ratio of 22.54, a PEG ratio of 2.63 and a beta of 1.34. MAXIMUS has a 12-month low of $51.74 and a 12-month high of $72.71.

MAXIMUS (NYSE:MMS) last announced its earnings results on Thursday, November 9th. The health services provider reported $0.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.04. MAXIMUS had a net margin of 8.54% and a return on equity of 23.97%. research analysts anticipate that MAXIMUS will post 3.05 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 28th. Investors of record on Thursday, February 15th will be paid a $0.045 dividend. This represents a $0.18 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date is Wednesday, February 14th. MAXIMUS’s payout ratio is presently 5.66%.

In other MAXIMUS news, General Counsel David Francis sold 3,900 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $63.97, for a total transaction of $249,483.00. Following the sale, the general counsel now directly owns 15,090 shares of the company’s stock, valued at approximately $965,307.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Russell A. Beliveau sold 1,500 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $64.30, for a total transaction of $96,450.00. Following the sale, the director now directly owns 40,329 shares in the company, valued at $2,593,154.70. The disclosure for this sale can be found here. Insiders have sold a total of 71,417 shares of company stock worth $4,902,785 over the last three months. Insiders own 3.10% of the company’s stock.

A number of large investors have recently modified their holdings of the business. GW&K Investment Management LLC lifted its position in MAXIMUS by 41.0% during the 4th quarter. GW&K Investment Management LLC now owns 60,739 shares of the health services provider’s stock worth $4,348,000 after buying an additional 17,661 shares in the last quarter. Mondrian Investment Partners LTD bought a new stake in MAXIMUS during the 4th quarter worth about $51,945,000. Acadian Asset Management LLC lifted its position in MAXIMUS by 5.4% during the 4th quarter. Acadian Asset Management LLC now owns 39,484 shares of the health services provider’s stock worth $2,827,000 after buying an additional 2,025 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in MAXIMUS by 5.3% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 726,384 shares of the health services provider’s stock worth $51,995,000 after buying an additional 36,570 shares in the last quarter. Finally, Bank of Montreal Can lifted its position in MAXIMUS by 6.7% during the 4th quarter. Bank of Montreal Can now owns 42,500 shares of the health services provider’s stock worth $3,042,000 after buying an additional 2,659 shares in the last quarter. 94.79% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “MAXIMUS (MMS) Lifted to Hold at Zacks Investment Research” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/21/maximus-mms-lifted-to-hold-at-zacks-investment-research.html.

About MAXIMUS

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Get a free copy of the Zacks research report on MAXIMUS (MMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply